U.S. stocks advanced Wednesday, October 21, with the Nasdaq Composite leading the major indexes as investors weighed strong results from SpaceX (NASDAQ: SPCX), renewed enthusiasm for artificial intelligence infrastructure and potential merger discussions involving Tesla (NASDAQ: TSLA). The Nasdaq gained 1.05%, the Dow Jones Industrial Average rose 0.69% and the S&P 500 added 0.58%, according to the supplied market-performance snapshot. The session highlighted a widening economic contrast: investors continued to reward the potential of AI spending, while elevated borrowing costs weighed on housing demand. Mortgage applications declined despite the first weekly drop in mortgage rates in more than two months.

Stock Market Closing Performance: October 21, 2026

The Nasdaq’s stronger advance relative to the Russell 2000 suggests investors favored technology-oriented exposure over smaller companies. Meanwhile, the Cboe Volatility Index, or VIX, declined 3.12% to 16.77 in the supplied snapshot, consistent with easing demand for near-term equity-market protection.

Treasury Yields, Oil, Gold and Bitcoin

These readings come from the attached screenshots; commodity and cryptocurrency prices are snapshot values rather than independently verified settlement prices. The Treasury move represents approximately three basis points increase in yield.

Why Stocks Rose: SpaceX Results Reinforce the AI Investment Case

SpaceX (NASDAQ: SPCX) provided one of the session’s clearest catalysts. The company reported third-quarter revenue of approximately $14.6 billion, up 161% from a year earlier and above the $12.72 billion consensus estimate cited by CNBC. Operating income reached $2.8 billion, while net income totaled $4.4 billion. The composition of that growth mattered as much as the headline numbers. SpaceX’s Super Intelligence business generated $7.56 billion in quarterly revenue, compared with $813 million a year earlier, making it the company’s largest business segment. Management also cited recurring revenue from its satellite-connectivity operations. For many, those results offered evidence that AI infrastructure demand can translate into substantial revenue, not merely larger construction budgets. Nevertheless, one company’s results do not establish that every AI infrastructure provider will earn attractive returns. Merger speculation added another layer. Elon Musk said SpaceX (NASDAQ: SPCX) and Tesla (NASDAQ: TSLA) had established special board committees to examine a possible combination. Those discussions do not constitute an agreed transaction, and Musk acknowledged the importance of shareholder support.

Macroeconomic Report: Lower Mortgage Rates Fail to Revive Demand

Wednesday’s housing-finance report delivered a more cautious message about the broader economy. The Mortgage Bankers Association reported that total mortgage applications fell 5.3% during the week ended October 16. The average contract rate on a conforming 30-year fixed mortgage declined to 7.41% from 7.50%, its first decrease in more than two months. The lower rate did not reverse the deterioration in demand:

• Applications to purchase a home fell 7% from the previous week.
• Purchase applications were 18% below their year-earlier level.
• Refinancing applications also declined.

The central issue remains affordability. A nine-basis-point weekly decline offers limited relief when mortgage rates remain above 7% and prospective buyers face substantial monthly payments. MBA economist Joel Kan attributed the year-over-year purchase slowdown to higher rates pricing buyers out of the market. The report also helps explain why a rising stock market does not necessarily signal an equally strong household economy. AI-related earnings can support major equity indexes even as rate-sensitive activity struggles. With the 10-year Treasury yield at 5.15%, Wednesday’s market snapshot showed little evidence of a broad retreat in long-term borrowing costs.

Meta and Tesla: Earnings Expectations, Not Reported Results

Meta: Advertising Growth Versus AI Spending

Meta’s (META) third quarter earnings, as revenue reached $64.6 billion, topping Wall Street’s $63.3 billion estimate. Third-quarter earnings of $9.86 billion. The Menlo Park, California-based company said it had profit of $3.83 per share. Earnings, adjusted for non-recurring costs, were $7.40 per share.

Tesla: Automotive Performance Meets Merger Speculation

Tesla (NASDAQ: TSLA) reported Q3 2026 earnings with $28 billion in revenue and announced that special committees are exploring a potential merger with SpaceX. Earnings per share: 48 cents adjusted vs. 43 cents estimated & Revenue: $28.05 billion vs. $27.9 billion estimated. Meanwhile, Tesla has started production of its Optimus humanoid robot at the Fremont facility and is targeting a 2028 launch for its new SpaceX-thruster-equipped Roadster. 

Nvidia’s Modular AI Infrastructure Targets Faster Deployment

Nvidia (NASDAQ: NVDA) introduced its DSX POD reference design at its Berlin GTC event, outlining a modular approach to bringing AI computing capacity online more quickly. According to Yahoo Finance’s report, Nvidia said the Vera Rubin-powered systems could reduce deployment time from approximately six months to 14 days once the required power, cooling and networking infrastructure is available. Initial deliveries are planned for early 2027. The economic rationale is straightforward: computing equipment cannot generate service revenue while it waits to become operational. Faster deployment could shorten that delay, although modular construction does not eliminate electricity constraints or the need for supporting infrastructure.

Anthropic IPO Plans Could Test Appetite for AI Risk

Anthropic, which remains privately held, but could publicly file its IPO prospectus as early as Friday, according to Yahoo Finance, citing people familiar with its plans. A potential November listing remains dependent on market conditions and other factors. Meanwhile, JPMorgan Chase (NYSE: JPM) analyst Doug Anmuth raised his SpaceX (NASDAQ: SPCX) price target to $500 from $240, according to Yahoo Finance. His thesis cited a combined potential addressable market exceeding $28 trillion across the company’s businesses. That figure represents an analyst’s estimate of market opportunity, not SpaceX revenue or a guaranteed outcome.

A Takeaway

Wednesday’s advance reflected confidence in AI-related growth, but the macroeconomic backdrop remained uneven. SpaceX’s results strengthened the revenue side of the AI investment argument, while declining mortgage applications showed that modest rate relief had not restored housing demand.

Today’s VP Watchlist Corporate Updates

Amwell® (NYSE: AMWL)

Amwell® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, closed at $13.97, +5.83%.

AMWL announced (Sept 8) announced the Department of Veterans Affairs (VA) has declared its intent for the Company to deploy its virtual health platform within the VA enterprise and help power the modernization of the VA’s digital health infrastructure. The VA anticipates the Amwell platform will support a broad range of clinical services, enhance care coordination, and improve access for our Veterans across the VA enterprise. The Letter of Intent follows a comprehensive evaluation process by the VA, in which it determined that Amwell’s virtual health platform aligns with the Department’s strategic objectives to expand access to high-quality, secure, and reliable virtual care services for Veterans nationwide through the VA’s current electronic health record modernization efforts. Specifically, the capabilities Amwell demonstrated in scalable video consultations, interoperability, cybersecurity compliance, and support for integrated care delivery were significant factors in this determination.

Amwell® has received Frost & Sullivan’s 2026 United States Technology Innovation Leadership Recognition in the Technology-Enabled Care Platforms Industry. The recognition validates Amwell’s ability to address healthcare fragmentation through a unified platform that orchestrates consumer experiences, clinician workflows, care programs, and partner solutions.

The Company also reiterated recently its objective to achieve positive cash flow from operations in the fourth quarter of 2026.

Serina Therapeutics (NYSE: SER)

Serina Theraeuptics (NYSE: SER, $177, +6.63%) is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina’s POZ PlatformTM provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology.

On Thursday, September 24, 2026, Serina CEO Steve Ledger discussed discuss Serina’s programs’ progress during Tribe Public’s “A New Approach to Advanced Parkinson’s Disease: Serina Discusses SER-252’s Clinical Progress”webinar, followed by a live Q&A. You may view it below.

SER announced (Sept. 9) that the independent Safety Monitoring Committee (SMC) has completed its blinded review of Cohort 1 of the ongoing Phase 1b registrational study of SER-252 in patients with advanced Parkinson’s disease and recommended that the study advance to Cohort 2. Cohort 1 evaluated the lowest dose level in the single-ascending-dose portion of the study. In addition to supporting continued dose escalation, blinded Cohort 1 observations showed a pharmacokinetic profile consistent with the sustained apomorphine exposure SER-252 is designed to provide and included sustained periods of improvement in motor function in individual patients on exploratory clinical measures.

Eupraxia Pharmaceuticals Inc. (EPRX)

Eupraxia Pharmaceuticals Inc. (EPRX, $7.73, +1.84%), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, announced (Oct. 15) that the ongoing RESOLVE study evaluating the safety and efficacy of EP-104GI for the treatment of Eosinophilic Esophagitis (“EoE”) has reached its enrollment target. “This is a significant milestone for the RESOLVE trial and the development of EP-104GI as a potential treatment option in EoE” said Dr. James Helliwell, Chief Executive Officer of Eupraxia. “We look forward to our interim analysis in December where we will be reporting on symptoms, histologic findings and safety in the first 60 patients in Phase 2b to reach 6 months. Data will also be available on the patients at 3, 9- and 12-month timepoints giving a fulsome interim look at the RESOLVE Trial”.

Modular Medical, Inc. (NASDAQ: MODD)

Modular Medical, Inc. (NASDAQ: MODD, $1.97, +1.03%), a commercial-stage medical device company preparing for the full commercial launch of its next-generation Pivot™ tubeless patch pump, announced (October 15) the launch of two innovative digital education resources designed to assist people living with diabetes build familiarity and confidence with insulin therapy ahead of formal training on the Pivot insulin delivery system. Developed in partnership with Relevate Health Games, the new tools use game-based technology to walk patients through the skills needed for insulin pump therapy. The resources are designed to help reduce barriers to adoption by allowing prospective users to become familiar with pump therapy before beginning formal onboarding. The first educational module gives users a virtual, hands-on walkthrough of the Pivot insulin delivery system. In approximately 15 minutes, users can visualize how to unpack the system, prepare and apply the pump, and understand the basic operational functions. The Pivot module was first previewed at the ADCES 2025 Annual Conference in August 2025. Healthcare providers may also use the platform to gauge a patient’s interest in pump therapy and ability to navigate basic operational tasks associated with insulin delivery devices. The experience offers clinicians valuable insight into patient engagement, learning readiness, and willingness to transition from multiple daily injections to a more advanced insulin delivery approach.

MODD announced (September 4) that it has secured a contract with a national U.S. pharmacy benefit manager (PBM) in the United States. Pursuant to the contract, the Company’s Pivot insulin delivery system is now available through the national PBM. The Company believes the engagement with this national PBM represents a significant step forward in broadening patient access to the Company’s Pivot tubeless patch pump and will further validate the Pivot pump as an accessible therapeutic option for people living with diabetes.

MODD announced (September 3) that the U.S. Food & Drug Administration (FDA) has cleared a set of software enhancements to its Pivot insulin delivery system, further expanding the system’s functionality and providing users with greater flexibility and customization options in bolus dosing, an enhanced user-interface (UI), and other software upgrades.

MODD CEO, Jeb Besser, co-hosted a Tribe Public’s CEO Presentation and Q&A Webinar Event titled “The Road To Revenue: Modular Medical’s Strategy For Launching Pivot,” that was held Friday, September 4, 2026.. You may watch the event video below now if you missed it below now.

Doximity, Inc. (NYSE:DOCS)

Doximity (NYSE: DOCS, $33.58, +.69%) is the leading digital platform for U.S. medical professionals. The company’s network members include more than 85% of U.S. physicians across all specialties and practice areas. Doximity provides its verified clinical membership with digital tools built for medicine, enabling them to collaborate with colleagues, stay current on medical news and research, manage their careers and on-call schedules, streamline documentation and administrative paperwork, and conduct virtual patient visits.

Doximity and Wolters Kluwer Health, announced (Oct. 20) that UpToDate’s trusted, evidence-based, clinical content will be accessible directly within Doximity’s fast-growing AI clinical decision support tool, Ask.

DOCS announced (Oct. 13) it has extended its 13-year partnership with U.S. News & World Report, the nation’s most trusted source of independent healthcare information, rankings and guidance to help patients identify the best care for their needs.

Nvidia (NVDA, $221.97, +2.54%)

NVIDIA Corp. (NASDAQ: NVDA), at its GTC event in Berlin on Wednesday, the company unveiled its DSX POD, a reference design for an AI data center packed into a box about the size of a standard shipping container. According to Nvidia, the Vera Rubin-powered DSX PODs will arrive on site, ready to be plugged into the power, cooling, and networking infrastructure, reducing deployment time from six months to 14 days. The company said DSX PODs won’t replace traditional data centers, but will serve as a means to start running AI applications before brick-and-mortar facilities are ready.

The Sources

1. CNBC: Stock Market Today: October 21, 2026 Live Updates
2. CNBC: Meta Q3 2026 Earnings: Live Updates
3. CNBC: Tesla Q3 2026 Earnings Report
4. CNBC: SpaceX Stock Rises Following Earnings and Potential Tesla Tie-Up
5. CNBC: Mortgage Rates Drop for the First Time in Two Months, but Demand Falls
6. Yahoo Finance: Why JPMorgan Thinks SpaceX Could Triple: A $28 Trillion Market Opportunity
7. Yahoo Finance: Anthropic Could Publicly File for an IPO as Early as Friday
8. Yahoo Finance: Nvidia Unveils Plans for Modular AI Infrastructure to Accelerate Data Center Deployment
9. Mortgage Bankers Association: Mortgage Applications Decrease in Latest MBA Weekly Survey
10. HousingWire: Mortgage Applications Drop 5.3% Despite Rate Decline